Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12343406-B2
Publication Date
2025-07-01
Expiration Date
Abstract
An immunoreactive substance carrier according to an embodiment of the present invention may stably deliver various immunoreactive substances including antibodies and/or cytokines, to a target site, thereby exhibiting excellent immunotherapeutic effects. Therefore, a composition including the immunoreactive substance carrier can be used for immunotherapy, thereby having excellent effects in the prevention or treatment of cancer or various immune diseases.
Core Innovation
The invention provides an immunotherapeutic composition in which an immunoreactive substance carrier includes expanded porous silica particles loaded with an immunoreactive substance comprised of at least one of an antibody or cytokine. The expanded porous silica particles carry the at least one of an antibody and cytokine, with an outer surface that is used as an outer surface of the immunoreactive substance carrier. The immunoreactive substance is supported on the outer surface and/or inside the pores of the expanded porous silica particles.
The expanded porous silica particles are defined by an average diameter ranging from 150 to 1,000 nm, a Brunauer-Emmett-Teller (BET) surface area ranging from 200 to 700 m2/g, and a volume per g ranging from 0.7 to 2.2 ml. The particles further have a characterization of durability/retention expressed by an absorbance ratio (At/A0) reaching 1/2 at a time t of 24 hours or more.
The invention positions the biodegradability and sustained release of immunoreactive substances upon degradation of the expanded porous silica particles as a rationale for therapeutic performance. It describes tunable surface chemistry with charged and hydrophilic/hydrophobic substituents, including support of immunoreactive substances on outer surfaces and/or inside pores.
Claims Coverage
The independent claim contains three core inventive features.
Expanded porous silica particles carrying an antibody and/or cytokine
The immunotherapeutic composition comprises an immunoreactive substance carrier loaded with an immunoreactive substance comprised of at least one of an antibody or cytokine, wherein the immunoreactive substance carrier comprises expanded porous silica particles which carry the at least one of an antibody and cytokine, and an outer surface of the immunoreactive substance carrier is an outer surface of the expanded porous silica particle.
Physicochemical parameter ranges for the expanded porous silica particles
The expanded porous silica particles have an average diameter ranging from 150 to 1,000 nm, a Brunauer-Emmett-Teller (BET) surface area ranging from 200 to 700 m2/g, and a volume per g ranging from 0.7 to 2.2 ml.
Retention characterization based on absorbance ratio at a degradation time
The expanded porous silica particles are characterized in that t, at which an absorbance ratio in Equation 1 becomes 1/2, is 24 hours or more, where At/A0 is based on absorbance measurements of the expanded porous silica particles using a 50 kDa permeable membrane arrangement with inside/outside contact and stirring under defined solvent conditions.
Antibody/cytokine support on outer surface and/or inside pores
The at least one of an antibody or cytokine is supported on the outer surface of the immunoreactive substance carrier and/or an inside of the pores.
Overall, the claims cover administering an immunotherapeutic composition where antibodies and/or cytokines are carried by expanded porous silica particles defined by specific size/surface/volume ranges, a retention metric expressed as an absorbance ratio threshold at t ≥ 24 hours, and localization of the antibody/cytokine on the outer surface and/or inside pores.
Stated Advantages
Provides sustained release upon biodegradation.
Preserves biological activity of IL-2.
Low hypersensitivity in vitro (MUSST hypersensitivity).
Stable delivery with tumor/immune-organ targeting as tracked by fluorescence.
Enhanced anti-tumor efficacy in multiple mouse cancer models.
Reduced cytokine-associated side effects (CLS/VLS) compared with free IL-2.
Documented Applications
Treating at least one of cancer and an immune disease by administering an immunotherapeutic composition comprising an immunoreactive substance carrier loaded with antibodies and/or cytokines.
Use in mouse cancer models including melanoma, with co-delivery to improve outcomes.
Interested in licensing this patent?